The science behind the probiotic strain bifidobacterium animalis subsp. Lactis bb-12®

Microorganisms

Volumn 2, Issue 2, 2014, Pages 92-110

  Jungersen, Mikkel ^a   Wind, Anette ^a   Johansen, Eric ^a   Christensen, Jeffrey E ^a   Stuer Lauridsen, Birgitte ^a   Eskesen, Dorte ^a  

^a CHR HANSEN A S   (Denmark)

Author keywords

BB 12 ; Bifidobacterium; Probiotic

Indexed keywords

EID: 84937002947     PISSN: None     EISSN: 20762607     Source Type: Journal    
DOI: 10.3390/microorganisms2020092     Document Type: Review

References (43)

1. Health and Nutrition Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria; FAO/WHO: Geneva, Switzerland, 2001.
2. Reuter, G. The Lactobacillus and Bifidobacterium microflora of the human intestine: Composition and succession. Curr. Issues Intest. Microbiol. 2001, 2, 43–53.
3. Garrigues, C.; Stuer-Lauridsen, B.; Johansen, E. Characterisation of Bifidobacterium animalis subsp. lactis BB-12 and other probiotic bacteria using genomics, transcriptomics and proteomics. Aust. J. Dairy Technol. 2005, 60, 84–92.
4. Garrigues, C.; Johansen, E.; Pedersen, M.B. Complete genome sequence of Bifidobacterium animalis subsp. lactis BB-12, a widely consumed probiotic strain. J. Bacteriol. 2010, 192, 2467–2468.
5. Pedersen, M.B.; Iversen, S.L.; Sorensen, K.I.; Johansen, E. The long and winding road from the research laboratory to industrial applications of lactic acid bacteria FEMS Microbiol. Rev. 2005, 29, 611–624.
6. Garrigues, C.; Johansen, E.; Crittenden, R. Pangenomics—An avenue to improved industrial starter cultures and probiotics. Curr. Opin. Biotechnol. 2013, 24, 187–191.
7. Vernazza, C.L.; Gibson, G.R.; Rastall, R.A. Carbohydrate preference, acid tolerance and bile tolerance in five strains of Bifidobacterium. J. Appl. Microbiol. 2006, 100, 846–853.
8. +-ATPase activity in Bifidobacterium with special reference to acid tolerance. Int. J. Food Microbiol. 2004, 93, 109–113.
9. Vinderola, C. Lactic acid starter and probiotic bacteria: A comparative “in vitro” study of probiotic characteristics and biological barrier resistance. Food Res. Int. 2003, 36, 895–904.
10. Laparra, J.M.; Sanz, Y. Comparison of in vitro models to study bacterial adhesion to the intestinal epithelium. Lett. Appl. Microbiol. 2009, 49, 695–701.
11. Rinkinen, M.; Westermarck, E.; Salminen, S.; Ouwehand, A.C. Absence of host specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus. Vet. Microbiol. 2003, 97, 55–61.
12. He, F.; Ouwehan, A.C.; Hashimoto, H.; Isolauri, E.; Benno, Y.; Salminen, S. Adhesion of Bifidobacterium spp. to human intestinal mucus. Microbiol. Immunol. 2001, 45, 259–262.
13. Juntunen, M.; Kirjavainen, P.V.; Ouwehand, A.C.; Salminen, S.J.; Isolauri, E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin. Diagn. Lab. Immunol. 2001, 8, 293–296.
14. Martins, F.S.; Silva, A.A.; Vieira, A.T.; Barbosa, F.H.; Arantes, R.M.; Teixeira, M.M.; Nicoli, J.R. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch. Microbiol. 2009, 191, 623–630.
15. Collado, M.C.; Meriluoto, J.; Salminen, S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett. Appl. Microbiol. 2007, 45, 454–460.
16. Collado, M.C.; Grzeskowiak, L.; Salminen, S. Probiotic strains and their combination inhibit in vitro adhesion of pathogens to pig intestinal mucosa. Curr. Microbiol. 2007, 55, 260–265.
17. Commane, D.M.; Shortt, C.T.; Silvi, S.; Cresci, A.; Hughes, R.M.; Rowland, I.R. Effects of fermentation products of pro-and prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon. Nutr. Cancer 2005, 51, 102–109.
18. Lopez, P.; Gueimonde, M.; Margolles, A.; Suarez, A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int. J. Food Microbiol. 2010, 138, 157–165.
19. Latvala, S.; Pietila, T.E.; Veckman, V.; Kekkonen, R.A.; Tynkkynen, S.; Korpela, R.; Julkunen, I. Potentially probiotic bacteria induce efficient maturation but differential cytokine production in human monocyte-derived dendritic cells. World J. Gastroenterol. 2008, 14, 5570–5581.
20. Matsumoto, M.; Hara, K.; Benno, Y. The influence of the immunostimulation by bacterial cell components derived from altered large intestinal microbiota on probiotic anti-inflammatory benefits. FEMS Immunol. Med. Microbiol. 2007, 49, 387–390.
21. Black, F.T. Placebo-Controlled Double-Blind Trial of 4 Lactobacilli Strains (HIP) Used as Prophylactic Agent against Traveller’s Diarrhea (2 Trials); Report by G. Nirnberger; Bioconsult: Vienna, Austria, 1996.
22. Palaria, A.; Johnson-Kanda, I.; O’Sullivan, D.J. Effect of a synbiotic yogurt on levels of fecal bifidobacteria, clostridia and enterobacteria. Appl. Environ. Microbiol. 2012, 78, 933–940.
23. Larsen, C.N.; Nielsen, S.; Kaestel, P.; Brockmann, E.; Bennedsen, M.; Christensen, H.R.; Eskesen, D.C.; Jacobsen, B.L.; Michaelsen, K.F. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp. paracasei CRL-341 in healthy young adults. Eur. J. Clin. Nutr. 2006, 60, 1284–1293.
24. Matto, J.; Fonden, R.; Tolvanen, T.; Vonwright, A.; Vilpponensalmela, T.; Satokari, R.; Saarela, M. Intestinal survival and persistence of probiotic Lactobacillus and Bifidobacterium strains administered in triple-strain yoghurt. Int. Dairy J. 2006, 16, 1174–1180.
25. Alander, M. Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract. Int. Dairy J. 2001, 11, 817–825.
26. Savard, P.; Lamarche, B.; Paradis, M.E.; Thiboutot, H.; Laurin, E.; Roy, D. Impact of Bifidobacterium animalis subsp. lactis BB-12 and, Lactobacillus acidophilus LA-5-containing yoghurt, on fecal bacterial counts of healthy adults. Int. J. Food Microbiol. 2011, 149, 50–57.
27. Pitkala, K.H.; Strandberg, T.E.; Finne Soveri, U.H.; Ouwehand, A.C.; Poussa, T.; Salminen, S. Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J. Nutr. Health Aging 2007, 11, 305–311.
28. Uchida, K.; Akashi, K.; Kusunoki, I.; Ikeda, T.; Katano, N.; Motoshima, H.; Benno, Y. Effect of fermented milk containing Bifidobacterium lactis BB-12® on stool frequency, defecation, fecal microbiota and safety of excessive ingestion in healthy female students. J. Nutr. Food 2005, 8, 39–51.
29. Nishida, S.; Gotou, M.; Akutsu, S.; Ono, M.; Hitomi, Y.; Nakamura, T.; Iino, H. Effect of yogurt containing Bifidobacterium lactis BB-12 on improvement of defecation and fecal microflora of healthy female adults. Milk Sci. 2004, 53, 71–80.
30. Matsumoto, M.; Imai, T.; Hironaka, T.; Kume, H.; Watanabe, M.; Benno, Y. Effect of yoghurt with Bifidobacterium lactis LKM512 in improving fecal microflora and defecation of healthy volunteers. Intest. Microbiol. Mag. 2001, 14, 97–102.
31. Chouraqui, J.P.; van Egroo, L.D.; Fichot, M.C. Acidified milk formula supplemented with Bifidobacterium lactis: Impact on infant diarrhea in residential care settings. J. Pediatr. Gastroenterol. Nutr. 2004, 38, 288–292.
32. Saavedra, J.M.; Bauman, N.A.; Oung, I.; Perman, J.A.; Yolken, R.H. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994, 344, 1046–1049.
33. Chatterjee, S.; Kar, P.; Das, T.; Ray, S.; Ganguly, S.; Rajendiran, C.; Mitra, M. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5® and Bifidobacterium BB-12® for prevention of antibiotic-associated diarrhoea. JAPI 2013, 61, 708–712.
34. De Vrese, M.; Kristen, H.; Rautenberg, P.; Laue, C.; Schrezenmeir, J. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J. Dairy Res. 2011, 78, 396–403.
35. Sheu, B.S.; Wu, J.J.; Lo, C.Y.; Wu, H.W.; Chen, J.H.; Lin, Y.S.; Lin, M.D. Impact of supplement with Lactobacillus-and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2002, 16, 1669–1675.
36. Wang, K.Y.; Li, S.N.; Liu, C.S.; Perng, D.S.; Su, Y.C.; Wu, D.C.; Jan, C.M.; Lai, C.H.; Wang, T.N.; Wang, W.M. Effects of ingesting Lactobacillus-and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am. J. Clin. Nutr. 2004, 80, 737–741.
37. Sheu, B.S.; Cheng, H.C.; Kao, A.W.; Wang, S.T.; Yang, Y.J.; Yang, H.B.; Wu, J.J. Pretreatment with Lactobacillus-and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am. J. Clin. Nutr. 2006, 83, 864–869.
38. Albers, R.; Antoine, J.M.; Bourdet-Sicard, R.; Calder, P.C.; Gleeson, M.; Lesourd, B.; Samartin, S.; Sanderson, I.R.; van Loo, J.; Vas Dias, F.W.; et al. Markers to measure immunomodulation in human nutrition intervention studies. Br. J. Nutr. 2005, 94, 452–481.
39. Burleson, G.R.; Burleson, F.G. Influenza virus host resistance model. Methods 2007, 41, 31–37.
40. Rizzardini, G.; Eskesen, D.; Calder, P.C.; Capetti, A.; Jespersen, L.; Clerici, M. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: A randomised, double-blind, placebo-controlled study. Br. J. Nutr. 2012, 107, 876–884.
41. Smith, T.J.; Rigassio-Radler, D.; Denmark, R.; Haley, T.; Touger-Decker, R. Effect of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections. Br. J. Nutr. 2013, 109, 1999–2007.
42. Taipale, T.; Pienihakkinen, K.; Isolauri, E.; Larsen, C.; Brockmann, E.; Alanen, P.; Jokela, J.; Soderling, E. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br. J. Nutr. 2011, 105, 409–416.
43. Rautava, S.; Salminen, S.; Isolauri, E. Specific probiotics in reducing the risk of acute infections in infancy—A randomised, double-blind, placebo-controlled study. Br. J. Nutr. 2009, 101, 1722–1726.